Study of DA-4505 alone or with pembrolizumab for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called DA-4505, given alone or with another drug (pembrolizumab), for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if it is safe and works against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced solid tumors that can be measured on scans.
- Your overall health allows you to be up and about (ECOG 0 or 1).
- You are expected to live at least 3 more months.
- You can take oral medications and have no major gut issues that affect absorption.
- You have not had certain cancer treatments recently (like CAR-T therapy or a stem cell transplant).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests ATG 037 to see if it’s safe and how it works in the body, as well as whether it may help people with advanced melanoma. It compares treatment given alone and treatment given together with pembrolizumab, especially in melanoma that has progressed after prior immunotherapy.
This trial tests a new drug called APX-343A, either by itself or in combination with the immunotherapy pembrolizumab, for people with advanced solid tumors that have not responded to prior treatments.
This early-stage trial tests a new investigational drug (ADG126) combined with pembrolizumab in people with advanced or metastatic solid tumors. It aims to find a safe dose and see whether the combination can shrink tumors.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This early study tests whether ADU-1805 is safe in people with advanced solid tumors and checks how the body processes the drug. Depending on your cancer type, it may also be looking specifically at certain cancers that have not yet received PD-(L)1 immunotherapy.
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.